Search research articles
Contact Us
Filters
Showing results (131-140 of 208) with videos related to
Page
of 21
Sort By:
Plos One
|
August 13, 2013
Population structure of mixed Mycobacterium tuberculosis infection is strain genotype and culture medium dependent
Madeleine Hanekom, Elizabeth M Streicher, Doreen Van de Berg, et al.
Experimental Dermatology
|
June 29, 2018
ATP6V0A2-related cutis laxa in 10 novel patients: Focus on clinical variability and expansion of the phenotype
Aude Beyens, Ester Moreno-Artero, Christine Bodemer, et al.
Viruses
|
November 25, 2023
Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters
Eduardo Gallardo-Toledo, Megan Neary, Joanne Sharp, et al.
Biorxiv : the Preprint Server for Biology
|
February 4, 2022
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Lee Tatham, Anja Kipar, Joanne Sharp, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 12, 2021
BDV Syndrome: An Emerging Syndrome With Profound Obesity and Neurodevelopmental Delay Resembling Prader-Willi Syndrome
Elisabeth Bosch, Moritz Hebebrand, Bernt Popp, et al.
The European Respiratory Journal
|
May 5, 2018
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa
Erika Mohr, Jennifer Hughes, Anja Reuter, et al.
Antimicrobial Agents and Chemotherapy
|
August 30, 2021
Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
Zubeida Salaam-Dreyer, Elizabeth M Streicher, Frederick A Sirgel, et al.
Microbiology Spectrum
|
July 16, 2024
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Lee Tatham, Anja Kipar, Jo Sharp, et al.
Journal of Clinical Microbiology
|
February 16, 2022
Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study
Helen Cox, Galo A Goig, Zubeida Salaam-Dreyer, et al.
The New England Journal of Medicine
|
May 30, 2019
Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment
Margaretha de Vos, Serej D Ley, Kristin B Wiggins, et al.
Page
of 21
Search research articles
Search
Showing results (131-140 of 208) with videos related to
Sort By:
Page
of 21
Plos One
|
August 13, 2013
Population structure of mixed Mycobacterium tuberculosis infection is strain genotype and culture medium dependent
Madeleine Hanekom, Elizabeth M Streicher, Doreen Van de Berg, et al.
Experimental Dermatology
|
June 29, 2018
ATP6V0A2-related cutis laxa in 10 novel patients: Focus on clinical variability and expansion of the phenotype
Aude Beyens, Ester Moreno-Artero, Christine Bodemer, et al.
Viruses
|
November 25, 2023
Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters
Eduardo Gallardo-Toledo, Megan Neary, Joanne Sharp, et al.
Biorxiv : the Preprint Server for Biology
|
February 4, 2022
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Lee Tatham, Anja Kipar, Joanne Sharp, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 12, 2021
BDV Syndrome: An Emerging Syndrome With Profound Obesity and Neurodevelopmental Delay Resembling Prader-Willi Syndrome
Elisabeth Bosch, Moritz Hebebrand, Bernt Popp, et al.
The European Respiratory Journal
|
May 5, 2018
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa
Erika Mohr, Jennifer Hughes, Anja Reuter, et al.
Antimicrobial Agents and Chemotherapy
|
August 30, 2021
Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
Zubeida Salaam-Dreyer, Elizabeth M Streicher, Frederick A Sirgel, et al.
Microbiology Spectrum
|
July 16, 2024
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Lee Tatham, Anja Kipar, Jo Sharp, et al.
Journal of Clinical Microbiology
|
February 16, 2022
Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study
Helen Cox, Galo A Goig, Zubeida Salaam-Dreyer, et al.
The New England Journal of Medicine
|
May 30, 2019
Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment
Margaretha de Vos, Serej D Ley, Kristin B Wiggins, et al.
Page
of 21